Lineage Therap (LCTX) Stock Statistics & Valuation Metrics
Total Valuation
Lineage Therap has a market cap or net worth of ILA 794.24M. The enterprise value is ILA 292.88M.
- Market Cap
- ILA 794.24M
- Enterprise Value
- ILA 292.88M
Share Statistics
Lineage Therap has 252,907,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 252,907,470
- Owned by Insiders
- 13.78%
- Owned by Institutions
- 17.33%
Financial Efficiency
Lineage Therap’s return on equity (ROE) is -1.43 and return on invested capital (ROIC) is -19.75%.
- Return on Equity (ROE)
- -1.43
- Return on Assets (ROA)
- -0.56
- Return on Invested Capital (ROIC)
- -19.75%
- Return on Capital Employed (ROCE)
- -0.22
- Revenue Per Employee
- 194.08K
- Profits Per Employee
- -847.11K
- Employee Count
- 75
- Asset Turnover
- 0.13
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lineage Therap is -7.20. Lineage Therap’s PEG ratio is 0.18.
- PE Ratio
- -7.20
- PS Ratio
- 19.52
- PB Ratio
- 4.14
- Price to FCF
- -10.67
- Price to Operating Cash Flow
- -10.58
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, Lineage Therap had revenue of 14.56M and earned -63.53M in profits. Earnings per share was -0.28.
- Revenue
- 14.56M
- Gross Profit
- 13.71M
- Operating Income
- -21.78M
- Pretax Income
- -68.65M
- Net Income
- -63.53M
- EBITDA
- -67.95M
- Earnings Per Share (EPS)
- -0.28
Cash Flow
In the last 12 months, operating cash flow was -23.82M and capital expenditures -123,000, giving a free cash flow of -23.94M billion.
- Operating Cash Flow
- -23.82M
- Free Cash Flow
- -23.94M
- Free Cash Flow per Share
- -0.10
Dividends & Yields
Lineage Therap pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.33%
- Earnings Yield
- -12.74%
Stock Price Statistics
- Beta
- 0.88
- 52-Week Price Change
- -48.94%
- 50-Day Moving Average
- 313.86
- 200-Day Moving Average
- 413.00
- Relative Strength Index (RSI)
- 49.93
- Average Volume (3m)
- 5,792
Important Dates
Lineage Therap upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Lineage Therap as a current ratio of 5.20, with Debt / Equity ratio of 5.43%
- Current Ratio
- 5.20
- Quick Ratio
- 5.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.56
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lineage Therap has paid -5.11M in taxes.
- Income Tax
- -5.11M
- Effective Tax Rate
- 0.07
Enterprise Valuation
Lineage Therap EV to EBITDA ratio is -6.05, with an EV/FCF ratio of -9.26.
- EV to Sales
- 16.94
- EV to EBITDA
- -6.05
- EV to Free Cash Flow
- -9.26
- EV to Operating Cash Flow
- -9.31
Balance Sheet
Lineage Therap has ILA 50.83M in cash and marketable securities with ILA 2.30M in debt, giving a net cash position of ILA 48.53M billion.
- Cash & Marketable Securities
- ILA 50.83M
- Total Debt
- ILA 2.30M
- Net Cash
- ILA 48.53M
- Net Cash Per Share
- ILA 0.19
- Tangible Book Value Per Share
- ILA 0.07
Margins
Gross margin is 96.59%, with operating margin of -205.23%, and net profit margin of -246.58%.
- Gross Margin
- 96.59%
- Operating Margin
- -205.23%
- Pretax Margin
- -285.75%
- Net Profit Margin
- -246.58%
- EBITDA Margin
- -280.10%
- EBIT Margin
- -285.75%
Analyst Forecast
The average price target for Lineage Therap is ILA 1,951.97, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- ILA 1,951.97
- Price Target Upside
- 535.61% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 6.09%
- EPS Growth Forecast
- 28.66%
Scores
- Smart Score
- 7
- AI Score
- ―
